RxDoctor Payments Data

Michael Schivo, MD

Critical Care Medicine · Sacramento, CANPI 1164407318

Payments from drug & device makers

$13,486in general payments, 2019–2025

Across 14 payments — averaging $963.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$13K
  • Boehringer Ingelheim$520
  • Regeneron Healthcare Solutions, Inc.$122
  • Pulmonx Corporation$89
  • Sunovion Pharmaceuticals Inc.$75
  • AbbVie$21
  • plus $33 from 2 others

What the payments were for

  • Consulting fees$52060%
  • Food & beverage$32137%
  • Education$192%

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,486 in reported general payments places this provider in the 85th percentile of 715 critical care medicine providers in California.

See all critical care medicine providers in California

Medicare billing

Part B allowed, 2024
$109,975
Medicare patients
465
Services billed
1,145

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Fasenra PenBenralizumab24$124,362
Breztri AerosphereBudesonide/Glycopyr/Formoterol123$93,677
Stiolto RespimatTiotropium Br/Olodaterol Hcl108$72,416
NucalaMepolizumab17$61,576
Spiriva RespimatTiotropium Bromide87$58,089
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr49$22,872
Advair HfaFluticasone Propion/Salmeterol49$22,233
SymbicortBudesonide/Formoterol Fumarate30$11,808
Incruse ElliptaUmeclidinium Bromide17$7,886
Breo ElliptaFluticasone/Vilanterol15$5,774
BreynaBudesonide/Formoterol Fumarate21$5,438
DuleraMometasone/Formoterol15$5,053
Fluticasone Propionate HfaFluticasone Propionate15$4,026
Albuterol Sulfate HfaAlbuterol Sulfate99$3,952
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate15$2,281

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$520$130,505195 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 715 critical care medicine providers in California.

Other critical care medicine in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →